BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChinaBio(R) LLC Week in Review: Three China In-Licensings and One Nixed Intra-China Deal


11/4/2013 8:59:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

November 2, 2013 --3SBio acquired China rights for a novel renal failure drug from the Shanghai Institute of Materia Medica; BioChain, a US-China clinical diagnostics company, purchased exclusive China rights to an in-vitro diagnostic test for colorectal cancer from Epigenomics of Germany; Bristol-Myers Squibb in-licensed exclusive China rights to market Coniel, a calcium channel blocker, from Kyowa Hakko Kirin of Japan; Sichuan Kelun Pharma will not complete its previously announced acquisition of a 20% stake in Lijun International Pharma; Charles River Labs purchased BRASS Pte Ltd, a Singapore-based microbiology test lab; China scientists have produced a flu vaccine for the H7N9 bird flu virus, and two China pharmas expressed interest in producing it; WuXi PharmaTech obtained GMP approval from the US FDA for a small molecule API and advanced intermediate CMO facility; Sanofi’s global revenues dropped 6.7% to $11.6 billion in Q3, though China sales were up a modest 5% to $477 million; and Cellular Biomedicine, a US-China stem cell company, is launching a kit in China that isolates stromal cells from adipose tissue. More details….

Stock Symbols: (F: ECX, OTC: EPGNY) (NYSE: BMY) (TYO: 4151) (SHE: 002422) (HK: 2005) (NYSE: CRL) (NYSE: WX) (NYSE: SNY) (OTCQB: CBMG)

Help employers find you! Check out all the jobs and post your resume.


Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES